Email this page

Print this page

Research Paper

A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy

Steven H. Sun, Min Zheng, Ke Ding, Shaomeng Wang and Yi Sun

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Mdm2 binds to p53 and promotes its degradation. A class of small molecule Mdm2 inhibitors (MI) was recently discovered that binds to Mdm2 and disrupts Mdm2-p53 binding. The efficacy of MI-43 was tested against two pairs of human lung cancer lines differing in p53 status: adenocarcinoma A549 (p53 wild-type, wt) and H522 (p53-null) and non-small cell lung carcinoma H460 (p53wt) and H1299 (p53-null). MI-43 induced the accumulation of p53 and its downstream target genes, Mdm2, p21, Noxa and Puma only in wt p53-containing cells, indicating that disruption of Mdm2-p53 binding increases p53, which is transcriptionally active. MI-43 preferentially inhibited the growth of wt p53-containing cells in a p53 dependent manner, but was much less effective in p53-null cells. Mechanistically, MI-43 induced G1 or G2 arrest at low concentration as result of p21 induction, and apoptosis at high concentration due to Puma/Noxa induction. Importantly, MI-43 is much less toxic to normal fetal lung fibroblast, MRC5 cells. Finally, when used in combination, MI-43 sensitized chemo-resistant A549 cells to etoposide-induced apoptosis. Thus, MI-43 or its analogues could be further developed as a novel class of anticancer drug for lung cancer cells harboring wt p53 as a single agent or in combination with chemo-drugs.

Authors

Steven H. Sun

Division of Cancer Biology, Department of Radiation Oncology, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 4304 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0936;

Min Zheng

Division of Cancer Biology, Department of Radiation Oncology

Ke Ding

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 4304 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0936;

Shaomeng Wang

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 4304 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0936;

Yi Sun

Division of Cancer Biology, Department of Radiation Oncology Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 4304 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0936;

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.